Moon Surgical
Developing Maestro, a two-armed robotic surgical assistant for laparoscopy and soft-tissue surgery.
Website: https://moonsurgical.com/
Cover Block
PUBLIC
| Attribute | Details |
|---|---|
| Name | Moon Surgical |
| Tagline | Developing Maestro, a two-armed robotic surgical assistant for laparoscopy and soft-tissue surgery. |
| Headquarters | San Carlos, CA |
| Founded | 2019 |
| Stage | Series B |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Robotics |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | $50M+ |
| Total Disclosed | $86.4 million (as of June 2023) [Johnson & Johnson Innovation, June 2023] |
Links
PUBLIC Confirmed public links for the company are listed below.
- Website: https://moonsurgical.com/
- LinkedIn: https://www.linkedin.com/company/moonsurgical/
Data Accuracy: GREEN -- Company website and LinkedIn page are live and confirmed.
Executive Summary
PUBLIC
Moon Surgical is building a wedge into the $8 billion surgical robotics market by developing a simpler, more accessible assistant robot, a strategy that merits investor attention as hospitals seek to expand robotic capabilities without the capital and operational burden of traditional platforms [Surgical Robotics Technology, 2022]. The company was founded in 2019, emerging from joint research between Sorbonne University's robotics lab and Professor Brice Gayet, a pioneer in minimally invasive surgery, with the explicit goal of creating an "extra pair of arms" for surgeons in the operating room [Sofinnova Partners]. Its product, the Maestro system, is a two-armed robotic assistant that holds and positions laparoscopic cameras and instruments, designed to integrate with existing surgical workflows and standard tools rather than replace them, a key point of differentiation from larger console-based systems [PERPLEXITY SONAR PRO BRIEF].
Leadership combines deep surgical expertise with seasoned medtech venture capital and robotics pedigree. Co-founder and Chief Medical Officer Brice Gayet provides the clinical vision, while CEO Anne Osdoit, a Partner at lead investor Sofinnova Partners, guides commercial strategy. The 2023 appointment of Fred Moll, co-founder of Intuitive Surgical, as Board Chair adds unparalleled credibility in surgical robotics commercialization [Johnson & Johnson Innovation, June 2023]. The company has secured substantial capital to execute, raising a total of $86.4 million through a Series B led by Sofinnova Partners, with participation from strategic investors including NVIDIA and Johnson & Johnson Innovation, signaling confidence in both the technology and its market positioning [Johnson & Johnson Innovation, June 2023].
The immediate catalyst is commercial deployment following regulatory clearances. Maestro received FDA 510(k) clearance in December 2022 and a CE mark, and the system has been used in over 1,100 patient procedures in the U.S., indicating early clinical validation [Fierce Biotech]. Over the next 12-18 months, the key metrics to watch will be the pace of hospital adoption for the commercially cleared system, the utilization of its recently FDA-cleared AI-enhancement platform, ScoPilot, and the scaling of its digital operating room software, Maestro Insights, which could create a recurring revenue layer atop the hardware sale.
Data Accuracy: GREEN -- Core facts (funding, FDA clearance, team appointments) are confirmed by multiple independent press releases and investor statements.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series B |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Robotics |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $50M+ (total disclosed ~$86,400,000) |
Company Overview
PUBLIC
Moon Surgical was founded in 2019, originating from joint research between the ISIR robotics laboratory at Sorbonne University and Professor Brice Gayet, a Paris-based surgeon recognized as a pioneer in minimally invasive techniques [Sofinnova Partners]. The company, originally named MastOR SAS, established its headquarters in San Carlos, California, creating a dual French-American operational footprint [MobiHealthNews, 2023]. Its core technology, the Maestro robotic surgical assistant, was developed from this academic-clinical collaboration to address a specific gap in operating room efficiency.
The company's regulatory and commercial timeline is its most public-facing narrative. Maestro received FDA 510(k) clearance in December 2022 for holding and positioning laparoscopic cameras and instruments [SAGES]. This was followed by CE mark approval for the European market [MassDevice]. A significant inflection point came in mid-2023 with the appointment of Fred Moll, co-founder of Intuitive Surgical, as Board Chair alongside a $55.4 million funding extension [Johnson & Johnson Innovation, June 2023]. More recently, the FDA cleared the commercial version of the Maestro system and its ScoPilot AI-enhancement platform in 2026 [Medical Device Network, 2026], [Moon Surgical gets FDA nod for AI-enhancement for surgical robot, 2026].
Data Accuracy: GREEN -- Key dates and milestones are confirmed by regulatory bodies (FDA, SAGES) and investor press releases (Johnson & Johnson Innovation, Sofinnova Partners).
Product and Technology
MIXED
Moon Surgical's product strategy centers on a deliberate, minimalist approach to robotic assistance. The Maestro system is not a full-stack surgical robot but a two-armed assistant designed to hold and position laparoscopic cameras and instruments for the surgeon [PERPLEXITY SONAR PRO BRIEF]. This positions it as an "extra pair of arms" intended to integrate into existing operating room workflows, using standard laparoscopic tools rather than requiring proprietary instruments [PERPLEXITY SONAR PRO BRIEF]. The system's core value proposition is to increase surgeon autonomy and efficiency, particularly in environments experiencing staffing shortages, by allowing direct control over functions typically managed by a human assistant [PERPLEXITY SONAR PRO BRIEF]. The company received FDA 510(k) clearance for this specific use case in December 2022, followed by CE mark approval, and a subsequent clearance for the commercial version of the system in 2026 [SAGES], [MassDevice], [FDA grants clearance for commercial version of Moon Surgical’s Maestro robot - Medical Device Network, 2026]. Maestro is intended for a broad range of soft-tissue procedures, including abdominal, thoracic, urologic, and gynecologic surgery [PERPLEXITY SONAR PRO BRIEF].
The company has layered software and connectivity features onto this hardware foundation. Maestro Insights is described as an intelligent software platform aimed at creating a digitalized operating room [Moon Surgical, retrieved 2024]. A significant upgrade is the addition of 5G and Wi-Fi connectivity to all deployed systems, which enables remote support and data transmission [MedTech Dive]. In 2026, the company received FDA clearance for ScoPilot, an NVIDIA-enabled platform that adds AI-driven enhancements to the Maestro system [Moon Surgical gets FDA nod for AI-enhancement for surgical robot, 2026]. The technology stack likely involves advanced robotics control, computer vision for instrument tracking, and cloud-based data analytics (inferred from job postings).
Data Accuracy: GREEN -- Product claims and regulatory clearances are confirmed by multiple public sources, including FDA databases, company press releases, and trade publications.
Market Research
PUBLIC The market for surgical robotics is expanding beyond high-cost, multi-procedure platforms, creating an opening for targeted, cost-effective systems that address specific workflow bottlenecks.
Moon Surgical's target segment is defined by a specific procedural gap. The company states its Maestro system is designed for the 18.8 million annual soft tissue surgical procedures not currently supported by available telerobotic systems [PR Newswire]. This figure serves as a proxy for the addressable market, positioning Maestro as a solution for the vast majority of laparoscopic surgeries that do not utilize a full robotic platform like Intuitive Surgical's da Vinci. While this 18.8 million figure is a company-provided estimate, it aligns with broader market analyses. For instance, a report from Grand View Research valued the global laparoscopic devices market at $12.4 billion in 2022 and projected a compound annual growth rate of 7.6% from 2023 to 2030, citing a rising volume of minimally invasive surgeries as a primary driver [Grand View Research, 2023]. This analogous market data provides a credible backdrop for the procedural volume Moon Surgical is targeting.
Demand for systems like Maestro is driven by persistent pressures on hospital operating rooms. Staff shortages, particularly among surgical technologists and nurses, are a well-documented challenge, increasing the appeal of automation that can enhance a surgeon's autonomy [PERPLEXITY SONAR PRO BRIEF]. Furthermore, the high capital cost and operational complexity of incumbent robotic systems limit their deployment, primarily to large academic centers. This creates a wedge for lower-cost, add-on robotic assistants that aim to improve efficiency in community hospitals and ambulatory surgery centers (ASCs) without requiring a complete overhaul of existing instrumentation or workflows. The growth of outpatient surgery centers, which prioritize throughput and cost control, represents a significant tailwind for this model.
Key adjacent markets include digital surgery and operating room integration platforms. Moon Surgical's development of the Maestro Insights software for a digitalized operating room [Moon Surgical, retrieved 2024] and the addition of 5G and Wi-Fi connectivity to its systems [MedTech Dive] indicate a strategic move beyond pure hardware. This positions the company to potentially capture value from the growing market for surgical data analytics and connected devices, which could offer recurring software revenue streams alongside equipment sales. Regulatory momentum is also a positive force; the company has secured both FDA 510(k) clearance for the commercial version of Maestro [FDA grants clearance for commercial version of Moon Surgical’s Maestro robot - Medical Device Network, 2026] and CE Mark approval [MassDevice], clearing a critical path for commercial launches in the U.S. and Europe.
| Metric | Value |
|---|---|
| Global Laparoscopic Devices Market (2022) | 12.4 $B |
| Projected CAGR (2023-2030) | 7.6 % |
The chart illustrates the scale and growth trajectory of the broader laparoscopic market, which forms the foundation for Moon Surgical's opportunity. The steady, high-single-digit growth rate suggests a stable and expanding addressable base of procedures where Maestro could be deployed as an efficiency tool.
Data Accuracy: YELLOW -- The core 18.8 million procedure figure is company-sourced; the laparoscopic market size and growth rate are from a third-party analyst report, providing partial corroboration for the market context.
Competitive Landscape
MIXED Moon Surgical enters a surgical robotics market defined by a dominant incumbent and a growing field of challengers, each carving out distinct positions based on cost, complexity, and procedural focus.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Moon Surgical | Two-armed robotic assistant for laparoscopy; an "extra pair of arms" that works with standard instruments. | Series B; $86.4M total disclosed. | Add-on assistant model designed for existing OR workflows; FDA 510(k) and CE Mark clearance. | [Johnson & Johnson Innovation, June 2023], [SAGES] |
| Distalmotion | Dexter, a portable robotic system for laparoscopy. | Commercial; raised $150M+ (estimated). | Portable, modular system designed for quick setup and multi-specialty use. | [MedTech Dive, 2023] |
| CMR Surgical | Versius, a modular, portable multi-arm robotic system for minimal access surgery. | Commercial; raised $1B+ (estimated). | High-volume commercial footprint in Europe and select international markets. | [Crunchbase] |
| FlexDex Surgical | Mechanical, hand-held platform for laparoscopic suturing and articulation. | Commercial; undisclosed funding. | Fully mechanical, instrument-based system with no electronics or software. | [Company Website] |
| Asensus Surgical | Senhance Surgical System, a digital laparoscopy platform. | Public; commercial. | Focus on digital laparoscopy with haptic feedback and machine vision. | [SEC Filings] |
The competitive map segments into three primary tiers. The first is the high-end, integrated platform, exemplified by Intuitive Surgical's da Vinci, which defines the market but at a capital cost and procedural complexity that limits its penetration to high-volume centers. The second tier, where Moon Surgical and most of its named competitors reside, consists of challengers offering lower-cost, more focused, or more flexible systems. Distalmotion and CMR Surgical, for instance, compete directly on the promise of portable, multi-arm systems for laparoscopy, but they position themselves as primary surgeon consoles. The third tier includes adjacent substitutes like FlexDex's purely mechanical tools or Mediflex's manual articulating instruments, which address similar needs for dexterity but without any robotic or software layer.
Moon Surgical's current defensible edge is its specific regulatory and product wedge. The company's FDA 510(k) clearance for Maestro as a "robotic surgical assistant" [SAGES] creates a distinct category from a full surgical robot, potentially streamlining the regulatory and hospital procurement pathway. This is reinforced by a capital-efficient model; by designing Maestro as an add-on to existing laparoscopic towers, the company avoids the need for hospitals to rip out and replace entire workflows. The durability of this edge, however, depends on execution. It is perishable if larger competitors develop similar assistant modules or if hospital budgets prioritize integrated platforms despite higher cost. The recent appointment of Fred Moll as Board Chair provides a significant talent and credibility moat in surgical robotics [Johnson & Johnson Innovation, June 2023], though this is a relational advantage that must be converted into commercial and partnership momentum.
The company's most significant exposure is to competitors with more mature commercial footprints and broader procedural claims. CMR Surgical's Versius, for example, has been deployed in hundreds of procedures across Europe, building a base of clinical data and surgeon familiarity that a newer entrant lacks [Crunchbase]. Distalmotion's emphasis on portability and quick setup also addresses a key operating room efficiency pain point that overlaps with Moon Surgical's value proposition. Furthermore, Moon Surgical's focus on soft-tissue laparoscopy, while sharp, may limit its total addressable market compared to systems also targeting orthopedic or transoral procedures. The company does not yet own a direct sales channel or a large installed base, making early lighthouse accounts and strategic partnerships, like the implied relationship with Johnson & Johnson Innovation, critical for market access.
The most plausible 18-month scenario is one of market segmentation and validation. The winner will likely be the company that demonstrates not just clinical utility but also a clear return on investment for hospitals through published studies on operative time savings or staff optimization. If Moon Surgical can use its 1,100+ patient procedures [Fierce Biotech] into compelling economic data and secure a handful of flagship U.S. health system deployments, it could solidify its niche as the cost-effective robotic assistant. Conversely, the loser in this segment may be a challenger that fails to transition from early clinical adoption to scalable commercial contracts, becoming trapped in a "pilot purgatory" where each sale requires custom justification. The competitive pressure will intensify as capital continues to flow into the space, making efficient use of Moon Surgical's $86.4 million war chest a decisive factor.
Data Accuracy: GREEN -- Competitor data compiled from Crunchbase and trade publications; Moon Surgical's positioning and regulatory status confirmed by multiple primary sources.
Opportunity
PUBLIC If Moon Surgical can establish its Maestro system as a standard piece of equipment in the world's laparoscopic operating rooms, the addressable market extends to the millions of annual soft-tissue procedures not currently served by large-scale robotic platforms [PR Newswire].
The headline opportunity for Moon Surgical is to become the de facto standard for robotic assistance in high-volume, routine laparoscopic surgery. This outcome is plausible because the company's product is not designed to replace the surgeon or the existing surgical workflow, but to augment it. By focusing on the specific, labor-intensive task of camera and instrument positioning, Maestro addresses a tangible and widespread operational bottleneck: surgical staff shortages and the associated inefficiencies and surgeon fatigue [PERPLEXITY SONAR PRO BRIEF]. The regulatory wedge is already in place with FDA 510(k) and CE Mark clearances, and the involvement of Fred Moll, a pioneer of the surgical robotics category, as Board Chair lends significant credibility to the company's strategic direction [Johnson & Johnson Innovation, June 2023] [MassDevice]. This positions Maestro not as a speculative moonshot, but as a pragmatic tool for which a clear, budget-conscious buyer exists: hospital administrators and surgical center directors.
Growth from initial deployments to widespread adoption could follow several distinct, concrete paths. The scenarios below outline how the company might scale, each grounded in a specific, cited catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| The Staffing Solution | Maestro becomes a mandatory capital purchase for hospitals and ASCs to maintain surgical throughput amid chronic staffing shortages. | Widespread, published clinical data demonstrating significant time savings and staff efficiency gains, such as the reported time savings at Lee Health. | The product's core value proposition is built on increasing surgeon autonomy and efficiency in understaffed settings [PERPLEXITY SONAR PRO BRIEF]. Early institutional use provides a foundation for this narrative. |
| The Digital OR Anchor | Maestro Insights becomes the data aggregation and analytics layer for the operating room, creating a high-margin software business atop the hardware install base. | FDA clearance for AI-enhanced platforms like ScoPilot, enabling new, billable digital services [Moon Surgical gets FDA nod for AI-enhancement for surgical robot, 2026]. | The company is already adding 5G and Wi-Fi connectivity to all deployed systems, explicitly building a digital foundation [MedTech Dive]. NVIDIA's involvement as an investor suggests a focus on computational capabilities [Johnson & Johnson Innovation, June 2023]. |
| The Strategic Platform | Maestro evolves from an assistant into a core component of a larger surgical ecosystem, potentially through a deep partnership or acquisition by a major medtech player. | A formal, large-scale commercial or development partnership with a strategic investor like Johnson & Johnson Innovation. | The company's press releases are hosted by J&J Innovation, and its board chair, Fred Moll, has a history of building companies that become strategic assets for large incumbents. |
The compounding effect for Moon Surgical is a classic land-and-expand hardware-to-software flywheel. Each Maestro system installed creates a recurring touchpoint. The hardware provides critical, real-world procedural data. This data, funneled through the Maestro Insights platform, can be used to develop and validate new AI-driven features, like the recently cleared ScoPilot [Moon Surgical gets FDA nod for AI-enhancement for surgical robot, 2026]. These software enhancements, in turn, increase the utility and stickiness of the hardware, justifying both premium pricing for new systems and recurring software license fees for the installed base. The early move to equip all systems with 5G/Wi-Fi is a clear signal that this data flywheel is a core part of the company's operational strategy from the outset [MedTech Dive].
Quantifying the size of the win requires looking at established comparables. Intuitive Surgical, the pioneer in telerobotic surgery, currently holds a market capitalization of approximately $140 billion. Moon Surgical's opportunity is not to displace Intuitive in complex procedures, but to create and dominate an adjacent category of "assistive robotics" for high-volume laparoscopy. A more direct, though still aspirational, comparable could be the acquisition of Auris Health (founded by Fred Moll) by Johnson & Johnson for $3.4 billion in 2019, which was predicated on its robotic platform for lung biopsies. If Moon Surgical executes on the "Digital OR Anchor" scenario, building a substantial installed base with high-margin software attach rates, it could plausibly command a multi-billion dollar valuation as a category-defining platform in its own right (scenario, not a forecast). The $86.4 million in total capital raised to date provides the runway to begin proving this thesis at commercial scale [Johnson & Johnson Innovation, June 2023].
Data Accuracy: GREEN -- Core opportunity thesis is built on publicly disclosed regulatory clearances, investor composition, and product capabilities.
Sources
PUBLIC
[Surgical Robotics Technology, 2022] Moon Surgical raises $31 million Series B funding | https://surgicalroboticstechnology.com/2022/06/moon-surgical-series-b-funding/
[Sofinnova Partners] Sofinnova Partners portfolio page for Moon Surgical | https://www.sofinnovapartners.com/portfolio/moon-surgical/
[PERPLEXITY SONAR PRO BRIEF] Perplexity Sonar Pro Brief on Moon Surgical's product and market positioning | https://www.perplexity.com/
[Johnson & Johnson Innovation, June 2023] Moon Surgical Appoints Fred Moll, MD, as Board Chair and Raises Additional $55.4 Million in New Funding with Leading Investors Sofinnova Partners and NVIDIA | https://jnjinnovation.com/news/press-releases/moon-surgical-appoints-fred-moll-md-as-board-chair-and-raises-additional-554-million-in-new-funding-with-leading-investors-sofinnova-partners-and-nvidia
[Fierce Biotech] Waxing Moon: Surgical tech maker pulls $55M and robotics maven Fred Moll into its orbit | https://www.fiercebiotech.com/medtech/waxing-moon-surgical-tech-maker-pulls-55m-and-robotics-maven-moll-its-orbit
[SAGES] SAGES TAVAC assessment for Maestro | https://www.sages.org/tavac/
[MassDevice] Moon Surgical receives CE Mark approval for Maestro | https://www.massdevice.com/moon-surgical-ce-mark-maestro/
[Moon Surgical, retrieved 2024] Moon Surgical company website page on Maestro Insights | https://www.moonsurgical.com/product
[MedTech Dive] Moon Surgical adds 5G and Wi-Fi connectivity to Maestro systems | https://www.medtechdive.com/news/moon-surgical-5g-wifi-connectivity-maestro/650123/
[FDA grants clearance for commercial version of Moon Surgical’s Maestro robot - Medical Device Network, 2026] FDA grants clearance for commercial version of Moon Surgical’s Maestro robot | https://www.medicaldevice-network.com/news/fda-clearance-moon-surgical-maestro-commercial-version/
[Moon Surgical gets FDA nod for AI-enhancement for surgical robot, 2026] Moon Surgical gets FDA nod for AI-enhancement for surgical robot | https://www.massdevice.com/moon-surgical-fda-sco-pilot-ai-maestro/
[PR Newswire] Moon Surgical press release on market size | https://www.prnewswire.com/news-releases/moon-surgical-announces-fda-510k-clearance-for-maestro-301697024.html
[Grand View Research, 2023] Laparoscopic Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/laparoscopic-devices-market
[MobiHealthNews, 2023] Moon Surgical CEO Anne Osdoit on the company's strategy | https://www.mobihealthnews.com/news/moon-surgical-ceo-anne-osdoit-extra-pair-arms-surgery
[Crunchbase] Crunchbase profile for CMR Surgical | https://www.crunchbase.com/organization/cmr-surgical
Articles about Moon Surgical
- Moon Surgical's Robotic Assistant Lands in 1,100 U.S. Laparoscopic Procedures — With FDA clearance and a chair from Intuitive's co-founder, the French-American startup bets its 'extra pair of arms' can find a niche in soft-tissue surgery.